278 related articles for article (PubMed ID: 22110734)
1. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
[TBL] [Abstract][Full Text] [Related]
2. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.
Atanackovic D; Hildebrandt Y; Jadczak A; Cao Y; Luetkens T; Meyer S; Kobold S; Bartels K; Pabst C; Lajmi N; Gordic M; Stahl T; Zander AR; Bokemeyer C; Kröger N
Haematologica; 2010 May; 95(5):785-93. PubMed ID: 20015885
[TBL] [Abstract][Full Text] [Related]
3. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.
Jungbluth AA; Ely S; DiLiberto M; Niesvizky R; Williamson B; Frosina D; Chen YT; Bhardwaj N; Chen-Kiang S; Old LJ; Cho HJ
Blood; 2005 Jul; 106(1):167-74. PubMed ID: 15761016
[TBL] [Abstract][Full Text] [Related]
4. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.
de Carvalho F; Alves VL; Braga WM; Xavier CV; Colleoni GW
Cancer Immunol Immunother; 2013 Jan; 62(1):191-5. PubMed ID: 23180015
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C; Zustin J; Jacobsen F; Luetkens T; Kröger N; Schilling G; Bokemeyer C; Sauter G; Atanackovic D; Marx A
Exp Mol Pathol; 2010 Oct; 89(2):175-81. PubMed ID: 20621094
[TBL] [Abstract][Full Text] [Related]
6. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition.
Tamura D; Arao T; Tanaka K; Kaneda H; Matsumoto K; Kudo K; Aomatsu K; Fujita Y; Watanabe T; Saijo N; Kotani Y; Nishimura Y; Nishio K
Cancer Sci; 2010 Jun; 101(6):1403-8. PubMed ID: 20367638
[TBL] [Abstract][Full Text] [Related]
8. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
9. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
[TBL] [Abstract][Full Text] [Related]
10. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
[TBL] [Abstract][Full Text] [Related]
11. [Effects of xbp-1 gene silencing on bortezomib-induced apoptosis in human multiple myeloma cells].
Yang Y; Dong HJ; Gao GX; Wang YW; Gu HT; Shu MM; Zhu HF; Chen XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1177-80. PubMed ID: 21129256
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.
Nara M; Teshima K; Watanabe A; Ito M; Iwamoto K; Kitabayashi A; Kume M; Hatano Y; Takahashi N; Iida S; Sawada K; Tagawa H
PLoS One; 2013; 8(3):e56954. PubMed ID: 23469177
[TBL] [Abstract][Full Text] [Related]
13. Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.
de Carvalho F; Vettore AL; Colleoni GW
Clin Dev Immunol; 2012; 2012():257695. PubMed ID: 22481966
[TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.
Perez LE; Parquet N; Meads M; Anasetti C; Dalton W
Eur J Haematol; 2010 Mar; 84(3):212-22. PubMed ID: 19922463
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
17. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.
Curioni-Fontecedro A; Nuber N; Mihic-Probst D; Seifert B; Soldini D; Dummer R; Knuth A; van den Broek M; Moch H
PLoS One; 2011; 6(6):e21418. PubMed ID: 21738656
[TBL] [Abstract][Full Text] [Related]
18. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
[TBL] [Abstract][Full Text] [Related]
19. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
20. Expression of cancer-testis antigen in multiple myeloma.
He L; Ji JN; Liu SQ; Xue E; Liang Q; Ma Z
J Huazhong Univ Sci Technolog Med Sci; 2014 Apr; 34(2):181-185. PubMed ID: 24710929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]